Showing results (101-110 of 167) with videos related to

Sort By:
Pageof 17
Blood|July 1, 1990
Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantationJ Nemunaitis, J W Singer, C D Buckner, et al.
Blood|September 1, 1993
Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factorJ Nemunaitis, K Shannon-Dorcy, F R Appelbaum, et al.
Journal of Translational Medicine|October 18, 2013
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignanciesJohn J Nemunaitis, Karen A Small, Paul Kirschmeier, et al.
Blood|December 1, 1993
Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantationJ Nemunaitis, F R Appelbaum, J W Singer, et al.
Pharmacoeconomics|June 7, 1994
Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer: an economic analysis of a randomised, double-blind, placebo-controlled trialB R Luce, J W Singer, J M Weschler, et al.
American Journal of Clinical Oncology|October 20, 2000
Cellular immune profile of patients with advanced cancer before and after taxane treatmentA W Tong, B Seamour, J M Lawson, et al.
Blood|May 1, 1991
Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantationJ Nemunaitis, C D Buckner, F R Appelbaum, et al.
Vaccines|October 6, 2020
Resident Memory T Cells and Their Effect on CancerDaniel J Craig, Justin F Creeden, Katelyn R Einloth, et al.
Bone Marrow Transplantation|October 1, 1994
Phase I study of recombinant human interleukin-1 beta (rhIL-1 beta) in patients with bone marrow failureJ Nemunaitis, M Ross, B Meisenberg, et al.
Human Gene Therapy|June 12, 1999
Phase I trial of interferon gamma retroviral vector administered intratumorally with multiple courses in patients with metastatic melanomaJ Nemunaitis, T Fong, F Burrows, et al.
Pageof 17